New-generation, non-SSRI antidepressants: Drug-drug interactions and therapeutic drug monitoring. Part 2: NaSSAs, NRIs, SNDRIs, MASSAs, NDRIs, and others.
drug-drug interactions
metabolism
metabolites
new-generation antidepressants (NGAs)
therapeutic drug monitoring (TDM)
Journal
Medicinal research reviews
ISSN: 1098-1128
Titre abrégé: Med Res Rev
Pays: United States
ID NLM: 8103150
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
25
10
2019
revised:
18
02
2020
accepted:
29
03
2020
pubmed:
15
4
2020
medline:
29
10
2021
entrez:
15
4
2020
Statut:
ppublish
Résumé
After the development of "classical" tricyclic antidepressants and monoamine oxidase inhibitors, numerous other classes of antidepressant drugs have been introduced onto the market. The selective serotonin reuptake inhibitor class is the best-known one, but many others exist, usually identified by their mechanism of activity. In this second part of the review, focused on new-generation antidepressants not included among selective serotonin reuptake inhibitors, the following classes are considered: noradrenergic and selective serotonergic antidepressants; norepinephrine reuptake inhibitors; serotonin, norepinephrine and dopamine reuptake inhibitors; melatonergic agonists and selective serotonergic antagonists; norepinephrine and dopamine reuptake inhibitors; and so forth. These different mechanisms underlie tolerability and safety profiles that can be very different among the classes, with each one providing significant advantages and disadvantages in comparison with others. The main characteristics of the following antidepressants are described: mianserin, mirtazapine, setiptiline, reboxetine, viloxazine, teniloxazine, atomoxetine, nefazodone, agomelatine, bupropion, esketamine, and tianeptine. The paper is focused on their metabolism and interactions, but also includes brief notes on analytical methods useful for their therapeutic drug monitoring.
Substances chimiques
Antidepressive Agents
0
Pharmaceutical Preparations
0
Serotonin Uptake Inhibitors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1794-1832Informations de copyright
© 2020 Wiley Periodicals, Inc.
Références
Morin RT, Nelson C, Bickford D, Insel PS, Mackin RS. Somatic and anxiety symptoms of depression are associated with disability in late life depression. Aging Ment Health. 2019;4:1-4.
Gahr M, Uzelac Z, Zeiss R, Connemann BJ, Lang D, Schönfeldt-Lecuona C. Linking annual prescription volume of antidepressants to corresponding web search query data: a possible proxy for medical prescription behavior? J Clin Psychopharmacol. 2015;35:681-685.
Rathod S, Pinninti N, Irfan M, et al. Mental health service provision in low- and middle-income countries. Health Serv Insights. 2017;10:1178632917694350.
Furukawa TA, Salanti G, Atkinson LZ, et al. Comparative efficacy and acceptability of first-generation and second-generation antidepressants in the acute treatment of major depression: protocol for a network meta-analysis. BMJ Open. 2016;6:e010919.
Luo Y, Chaimani A, Kataoka Y, et al. Evidence synthesis, practice guidelines and real-world prescriptions of new generation antidepressants in the treatment of depression: a protocol for cumulative network meta-analyses and meta-epidemiological study. BMJ Open. 2018;8:e023222.
Stahl SM. Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects. J Affect Disord. 1998;51:215-235.
Malberg JE, Blendy JA. Antidepressant action: to the nucleus and beyond. Trends Pharmacol Sci. 2005;26:631-638.
Racagni G, Popoli M. Cellular and molecular mechanisms in the long-term action of antidepressants. Dialogues Clin Neurosci. 2008;10:385-400.
Tylee A, Walters P. Onset of action of antidepressants. BMJ. 2007;334:911-912.
Li Y-F. Strategy for development of fast-onset antidepressive agents: candidate hypothesis of monoamine (5-HT)-nonmonoamine (Glu/GABA) long-feedback neural circuit. Chinese J Pharmacol Toxicol. 2019;33:161-173.
Garay RP, Zarate CA Jr, Charpeaud T, et al. Investigational drugs in recent clinical trials for treatment-resistant depression. Expert Rev Neurother. 2017;17:593-609.
Fabbri C, Porcelli S, Serretti A. From pharmacogenetics to pharmacogenomics: the way toward the personalization of antidepressant treatment. Can J Psychiat. 2014;59:62-75.
Cantrell CR, Eaddy MT, Shah MB, Regan TS, Sokol MC. Methods for evaluating patient adherence to antidepressant therapy: a real-world comparison of adherence economic outcomes. Med Care. 2006;44:300-303.
Thase ME. Evaluating antidepressant therapies: remission as the optimal outcome. J Clin Psychiat. 2003;64:18-25.
Fabbri C, Kasper S, Kautzky A, et al. A polygenic predictor of treatment-resistant depression using whole exome sequencing and genome-wide genotyping. https://www.medrxiv.org/content/10.1101/19007161v1 Accessed October 10, 2019.
Mitchell PB. Therapeutic drug monitoring of psychotropic medications. Br J Clin Pharmacol. 2001;52:45-54.
Raggi MA, Mandrioli R, Sabbioni C, Pucci V. Atypical antipsychotics: pharmacokinetics, therapeutic drug monitoring and pharmacological interactions. Curr Med Chem. 2004;11:279-296.
Albers LJ, Ozdemir V. Pharmacogenomic-guided rational therapeutic drug monitoring: conceptual framework and application platforms for atypical antipsychotics. Curr Med Chem. 2004;11:297-312.
Bauer M, Severus E, Köhler S, Whybrow PC, Angst J, Möller HJ. WFSBP task force on treatment guidelines for unipolar depressive disorders. World federation of societies of biological psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders. Part 2: maintenance treatment of major depressive disorder-update 2015. World J Biol Psychiat. 2015;12:76-95.
Conca A, Schmidt E, Pastore M, Hiemke C, Duffy D, Giupponi G. Therapeutic drug monitoring in Italian psychiatry. Pharmacopsychiatry. 2011;44:259-262.
Wong SHY, Sunshine I. Handbook of Analytical Therapeutic Drug Monitoring and Toxicology. Boca Raton, FL: CRC Press; 1997:368.
Raggi MA, Mandrioli R, Pucci V, Sabbioni C. Advances in therapeutic drug monitoring of atypical antipsychotic drugs. Med Chem Rev Online. 2004;1:299-316.
Mandrioli R, Protti M, Mercolini L. Novel atypical antipsychotics: metabolism and therapeutic drug monitoring (TDM). Curr Drug Metab. 2014;16:141-151.
Mandrioli R, Protti M, Mercolini L. Metabolic syndrome in schizophrenia: focus on the role of antipsychotic medications and indications for therapeutic drug monitoring (TDM) methods. In: Frontiers in Clinical Drug Research - Diabetes and Obesity Vol. 5. Sharjah: Bentham Science Publishers; 2020. In press. DOI: 10.2174/97816810875351190501
Mercolini L, Protti M, Fulgenzi G, et al. A fast and feasible microextraction by packed sorbent (MEPS) procedure for HPLC analysis of the atypical antipsychotic ziprasidone in human plasma. J Pharmaceut Biomed. 2014;88:467-471.
Mandrioli R, Mercolini L, Raggi MA. Benzodiazepine metabolism: an analytical perspective. Curr Drug Metab. 2008;9:827-844.
Mandrioli R, Mercolini L, Raggi MA. Metabolism of benzodiazepine and non-benzodiazepine anxiolytic-hypnotic drugs: an analytical point of view. Curr Drug Metab. 2010;11:815-829.
Mandrioli R, Mercolini L. Metabolism of drugs used in the therapy of seizures: an analytical point of view. Part 1. Curr Drug Metab. 2017;18(8):735-756.
Capuano B, Crosby IT, Lloyd EJ. Schizophrenia: genesis, receptorology and current therapeutics. Curr Med Chem. 2002;9:521-548.
Mandrioli R, Mercolini L, Saracino MA, Raggi MA. Selective serotonin reuptake inhibitors (SSRIs): therapeutic drug monitoring and pharmacological interactions. Curr Med Chem. 2012;19:1846-1863.
Wille SMR, Cooreman SG, Neels HM, Lambert WEE. Relevant issues in the monitoring and the toxicology of antidepressants. Crit Rev Clin Lab Sci. 2008;45:25-89.
Baumann P, Hiemke C, Ulrich S, et al. Arbeitsgemeinschaft für neuropsychopharmakologie und pharmakopsychiatrie. The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry. 2004;37:243-265.
Hiemke C, Bergemann N, Clement HW, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018;51:9-62.
Mandrioli R, Protti M, Mercolini L. New-generation, non-SSRI antidepressants: therapeutic drug monitoring and pharmacological interactions. Part 1: SNRIs, SMSs, SARIs. Curr Med Chem. 2018;25:772-792.
Elsevier BV, Scopus document search 2019. https://www.scopus.com/home.uri. Accessed September 10, 2019.
National Center for Biotechnology Information. PubMed Search 2019. https://www.ncbi.nlm.nih.gov/pubmed. Accessed September 10, 2019.
Medicines.org.au, Tolvon product information. http://www.medicines.org.au/files/mkptolvo.pdf. Accessed September 10, 2019.
Olumuyiwa JF. The emergence of new antidepressants for clinical use: Agomelatine paradox versus other novel agents. IBRO Reports. 2019;6:95-110.
Ban TA, ed. (Ed.). An oral history of neuropsychopharmacology. The first fifty years. Vol. 9: Update. Brentwood: American College of Neuropshychopharmacology; 2011.
Drugbank. Drug interaction lookup. https://www.drugbank.ca/interax/drug_lookup. Accessed September 10, 2019.
Demling J. Mianserin: pharmacology and clinical aspects of an effective antidepressive agent. Fortschr Med. 1993;111:497-500.
Richelson E, Nelson A. Antagonism by antidepressants of neurotransmitterreceptors of normal human brain in vitro. J Pharmacol Exp Ther. 1984;230:94-102.
Olianas MC, Dedoni S, Onali P. The atypical antidepressant mianserin exhibits agonist activity at κ-opioid receptors. Br J Pharmacol. 2012;167:1329-1341.
Herman I, Shamir D, Bar-Hamburger R, Pick CG, Schreiber S. The effect of mianserin add-on, on the intensity of opioid withdrawal symptoms during detoxification program - a randomized, double blind, placebo controlled, prospective study. Addictive Behav. 2005;30:1154-1167.
Pinder RM, van Delft AM. Pharmacological aspects of mianserin. Acta Psychiatr Scand Suppl. 1983;302:59-71.
Koyama E, Chiba K, Tani M, Ishizaki T. Identification of human cytochrome P450 isoforms involved in the stereoselective metabolism of mianserin enantiomers. J Pharmacol Exp Ther. 1996;278:21-30.
Chow T, Hiroi T, Imaoka S, Chiba K, Funae Y. Isoform-selective metabolism of mianserin by cytochrome P-450 2D. Drug Metab Dispos. 1999;27:1200-1204.
Otani K, Sasa H, Kaneko S, Kondo T, Fukushima Y. Steady-state plasma concentrations of mianserin and its major active metabolite, desmethylmianserin. Ther Drug Monit. 1993;15:113-117.
Poleszak E, Szopa A, Wyska E, et al. Caffeine augments the antidepressant-like activity of mianserin and agomelatine in forced swim and tail suspension tests in mice. Pharmacol Rep. 2016;68:56-61.
Socała K, Nieoczym D, Wyska E, Poleszak E, Wlaź P. Sildenafil, a phosphodiesterase type 5 inhibitor, enhances the activity of two atypical antidepressant drugs, mianserin and tianeptine, in the forced swim test in mice. Prog. Neuro-Psychoph. 2012;38:121-126.
Stasiuk W, Serefko A, Szopa A, et al. Traxoprodil augments the antidepressant-like activity of agomelatine but not of mianserin or tianeptine in the forced swim test in mice. Pharmacol Rep. 2016;68:960-963.
Górska D, Andrzejczak D. Influence of mianserin on the activity of some hypotensive drugs in spontaneously hypertensive rats. Polish J Pharmacol. 2003;55:409-417.
Pakulska W, Czarnecka E. Influence of mianserin on the antinociceptive effect of morphine, metamizol and indomethacin in mice. Pharmacol Res. 2002;46:415-423.
Montgomery S, McAuley R, Montgomery DB. Relationship between mianserin plasma levels and antidepressant e ect in a double-blind trial comparing a single night-time and divided daily dose regimens. Br J Clin Pharmacol. 1978;5(Suppl 1):71S-76S.
Xu P, Li H-D, Chen B-M, Ma N, Yan M, Zhu Y-G. Determination of mianserin in human plasma by high performance liquid chromatography-electrospray ionization mass spectrometry (HPLC-ESI/MS): application to a bioequivalence study in Chinese volunteers. J Pharmaceut Biomed. 2008;47:994-999.
Chauhan B, Rani S, Guttikar S, Zope A, Jadon N, Padh H. Analytical method development and validation of mianserin hydrochloride and its metabolite in human plasma by LC-MS. J Chromatogr B. 2005;823:69-74.
Hefnawy MM, Aboul-Enein HY. Fast high-performance liquid chromatographic analysis of mianserin and its metabolites in human plasma using monolithic silica column and solid phase extraction. Anal Chim Acta. 2004;504:291-297.
Łukaszkiewicz J, Piwowarska J, Skarzyńka E, Łojewska MS, Pachecka J. Development, validation and application of the HPLC method for determination of mianserin in human serum. Acta Pol Pharm - Drug Res. 2007;64:103-107.
Grodner B, Pachecka J. A simpler and faster capillary electrophoresis method for determination of mianserin enantiomers in human serum. Acta Pol Pharm- Drug Res. 2006;63:9-14.
Ishii A, Kurihara R, Kojima T, et al. Sensitive determination of mianserin and setiptiline in body fluids by gas chromatography with surface ionizations detection (GC-SID). Legal Med. 2000;2:115-118.
Li W, Wu D, Chen S, Peng H, Guan Y. Study of the surface ionization detector for gas chromatography. J Chromatogr A. 2011;1218:6812-6816.
Food and Drug Administration, Mirtazapine Approval History. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#apphist. Accessed September 10, 2019.
Liappas J, Paparrigopoulos T, Tzavellas E, Christodoulou G. Alcohol detoxification and social anxiety symptoms: a preliminary study of the impact of mirtazapine administration. J Affect Disord. 2003;76:279-284.
Poyurovsky M, Epshtein S, Fuchs C, Schneidman M, Weizman R, Weizman A. Efficacy of low-dose mirtazapine in neuroleptic-induced akathisia: a double-blind randomized placebo-controlled pilot study. J Clin Psychopharmacol. 2003;23:305-308.
Anttila SA, Leinonen EV. A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 2001;7:249-264.
Wan DD, Kundhur D, Solomons K, Yatham LN, Lam RW. Mirtazapine for treatment-resistant depression: a preliminary report. J Psychiatry Neurosci. 2003;28:55-59.
Van Hensbeek I, Van Oers H, Schutte AJ. Early onset of action of mirtazapine versus other new-generation antidepressants for patients in remission. Eur Neuropsychopharm. 2002;12:187. -187.
Raggi MA, Mandrioli R, Pucci V. New trends in the treatment of depression: pharmacological profiles of selective serotonin reuptake inhibitors. Curr Trends Med Chem. 2003;3:203-220.
Wheatley DP, van Moffaert M, Timmerman L, Kremer CM. Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. J Clin Psychiat. 1998;59:306-312.
Störmer E, von Moltke LL, Shader RI, Greenblatt DJ. Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochromes P-450 1A2, 2D6, and 3A4. Drug Metab Dispos. 2000;28:1168-1175.
Dodd S, Boulton DW, Burrows GD, De Vane CL, Norman TR. In vitro metabolism of mirtazapine enantiomers by human cytochrome P450 enzymes. Hum Psychopharmacol. 2001;16:541-544.
Delbressine LP, Moonen ME, Kaspersen FM, et al. Pharmacokinetics and biotransformation of mirtazapine in human volunteers. Clin Drug Investig. 1998;15:45-55.
Delbressine LP, Vos RM. The clinical relevance of preclinical data: mirtazapine, a model compound. J Clin Psychopharmacol. 1997;17S1:29S-33S.
Dahl M-L, Voortman G, Alm C, et al. In vitro and in vivo studies on the disposition of mirtazapine in humans. Clin Drug Invest. 1997;13:37-46.
Moody JD, Freeman JP, Fu PP, Cerniglia CE. Biotransformation of mirtazapine by Cunninghamella elegans. Drug Metab Dispos. 2002;30:1274-1279.
Holzbach R, Jahn H, Pajonk FG, Mähne C. Suicide attempts with mirtazapine overdose without complications. Biol Psychiat. 1998;44:925-926.
Nutt DJ. Tolerability and safety aspects of mirtazapine. Hum Psychopharmacol. 2002;17S1:S37-S41.
Sweetman SC, ed. Martindale The Complete Drug Reference. 34 ed. London, UK: Pharmaceutical Press; 2004:299.
Health Canada, Health Canada advises canadians of stronger warnings for SSRIs and other newer anti-depressants. https://www.canada.ca/en/news/archive/2004/06/health-canada-advises-canadians-stronger-warnings-ssris-other-newer-anti-depressants.html. Accessed September 10, 2019.
Devi S. Antidepressant-suicide link in children questioned. Lancet. 2012;379:791.
Loonen AJ, Doorschot CH, Oostelbos MC, Sitsen JM. Lack of drug interactions between mirtazapine and risperidone in psychiatric patients: a pilot study. Eur Neuropsychopharmacol. 1999;10:51-57.
Zoccali R, Muscatello MR, Torre DL, et al. Lack of a pharmacokinetic interaction between mirtazapine and the newer antipsychotics clozapine, risperidone and olanzapine in patients with chronic schizophrenia. Pharmacol Res. 2003;48:411-414.
Paulzen M, Haen E, Hiemke C, et al. Antidepressant polypharmacy and the potential of pharmacokinetic interactions: doxepin but not mirtazapine causes clinically relevant changes in venlafaxine metabolism. J Affect Disorders. 2017;227:506-511.
Lo Presti C, Laguin S, Bambina E, Arlotto E, Aghazarian V, Guise-Honore S. Case report: pharmacokinetic interaction between clozapine and mirtazapine. Encephale. 2019;45(4):363-364.
Ginsberg DL. Mirtazapine-risperidone combination associated with pulmonary thromboembolism and rhabdomyolysis. Prim Psychiat. 2006;13:25-26.
Abbasi SH, Behpournia H, Ghoreshi A, et al. The effect of mirtazapine add on therapy to risperidone in the treatment of schizophrenia: a double-blind randomized placebo-controlled trial. Schizophr Res. 2010;116:101-106.
Cho SJ, Yook K, Kim B, et al. Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: a randomized controlled trial. Prog Neuro-Psychoph. 2011;35:208-211.
Stenberg J-H, Terevnikov V, Joffe M, et al. More evidence on proneurocognitive effects of add-on mirtazapine in schizophrenia. Prog Neuro-Psychoph. 2011;35:1080-1086.
Terevnikov V, Stenberg JH, Tiihonen J, et al. Add-on mitrazapine improves depressive symptoms in schizophrenia: a double-blind placebo-controlled study with an open label extension phase. Hum Psychopharmacol. 2011;26:188-193.
Berk M, Gama CS, Sundram S, et al. Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: a double-blind, randomised, placebo-controlled clinical trial. Hum Psychopharmacol. 2009;24:233-238.
Rogóz Z. Effect of combined treatment with mirtazapine and risperidone on the MK-801-induced changes in the object recognition test in mice. Pharmacol Rep. 2013;65:1401-1406.
Page RL 2nd, Ruscin JM, Bainbridge JL, Brieke AA. Restless legs syndrome induced by escitalopram: case report and review of the literature. Pharmacotherapy. 2008;28:271-280.
Prospero-Garcia KA, Torres-Ruiz A, Ramirez-Bermudez J, Yelazquez-Moctezuma J, Arana-Lechuga Y, Teran-Perez G. Fluoxetine-mirtazapine interaction may induce restless legs syndrome: report of 3 cases from a clinical trial. J Clin Psychiat. 2006;67:1820.
Orlandi V, Speca A, Salviati M, Biondi M. Abnormal prolactin elevation in a schizophrenic patient in treatment with quetiapine and mirtazapine. The role of the opioid system. J Clin Psychopharmacol. 2003;23:677-679.
Nishimura H, Kawakami M. A case with the Increased PT-INR after the addition of mirtazapine to warfarin therapy. Psychiat Neurol Japon. 2015;117:820-825.
Rajpurohit N, Aryal SR, Khan MA, Stys AT, Stys TP. Propafenone-associated severe central nervous system and cardiovascular toxicity due to mirtazapine: a case of severe drug interaction. South Dakota Med. 2014;67:137-139.
Koch H, Nanev D. Important interaction between mirtazapine and ondansetron. Afr J Psychiatry. 2012;15:160. -160.
Lozano R. Mirtazapine and ondansetron: a dual pharmacodynamic and pharmacokinetic interaction. Afr J Psychiatry. 2013;16:56.
Fraile P, Garcia-Cosmes P, Garcia T, Corbacho L, Alvarez M, Tabernero JM. Hypotension, as consequence of the interaction between tacrolimus and mirtazapine, in a patient with renal transplant. Nephrol Dial Transpl. 2009;24:1999-2001.
Barbosa-Méndez S, Matus-Ortega M, Salazar-Juárez A. Synergistic interactions between mirtazapine and prazosin prevent the induction and expression of behavioral sensitization to cocaine in rats. Physiol Behav. 2017;180:137-145.
Andrzejczak D, Kocon K, Ziȩba R. Influence of mirtazapine on the hypotensive activity of enalapril and propranolol in spontaneously hypertensive rats. Basic Clin Pharmacol. 2008;103:450-454.
Thakar BN, Shah K, Desai U, Suresh DK, Rawal R, Khalid S. Modulation in pharmacokinetic properties of mirtazapine and citalopram during contemporaneous therapy with ritonavir. J Pharmacol Toxicol. 2012;7:29-37.
Grasmader K, Verwohlt PL, Kuhn KU, et al. Relationship between mirtazapine dose, plasma concentration, response, and side effects in clinical practice. Pharmacopsychiatry. 2005;38:113-117.
Ptácek P, Klíma J, Macek J. Determination of mirtazapine in human plasma by liquid chromatography. J Chromatogr B. 2003;794:323-328.
Dodd S, Burrows GD, Norman TR. Chiral determination of mirtazapine in human blood plasma by high-performance liquid chromatography. J Chromatogr B. 2000;748:439-443.
Paus E, Jonzier-Perey M, Cochard N, Eap CB, Baumann P. Chirality in the new generation of antidepressants: stereoselective analysis of the enantiomers of mirtazapine, N-demethylmirtazapine, and 8-hydroxymirtazapine by LC-MS. Ther Drug Monit. 2004;26:366-374.
Pistos C, Koutsopoulou M, Panderi I. Validated liquid chromatography-tandem mass spectrometry method for the determination of mirtazapine and demethylmirtazapine in human plasma: application to a pharmacokinetic study. Anal Chim Acta. 2004;514:15-26.
Romiguieres T, Pehourcq F, Matoga M, Begaud B, Jarry C. Determination of mirtazapine and its demethyl metabolite in plasma by high-performance liquid chromatography with ultraviolet detection. Application to management of acute intoxication. J Chromatogr B. 2002;775:163-168.
Maris FA, Dingler E, Niehues S. High-performance liquid chromatographic assay with fluorescence detection for the routine monitoring of the antidepressant mirtazapine and its demethyl metabolite in human plasma. J Chromatogr B. 1999;721:309-316.
Mandrioli R, Mercolini L, Ghedini N, Bartoletti C, Fanali S. Raggi MA.Determination of the recent antidepressant mirtazapine and its two main metabolites in human plasma by liquid chromatography with fluorescence detection. Anal Chim Acta. 2006;556:281-288.
Meineke I, Kress I, Poser W, Rüther E, Brockmöller J. Therapeutic drug monitoring of mirtazapine and its metabolite desmethylmirtazapine by HPLC with fluorescence detection. Ther Drug Monit. 2004;26:277-283.
Shams M, Hiemke C, Härtter S. Therapeutic drug monitoring of the antidepressant mirtazapine and its N-demethylated metabolite in human serum. Ther Drug Monit. 2004;26:78-84.
Morgan PE, Tapper J, Spencer EP. Measurement of total mirtazapine andnormirtazapine in plasma/serum by liquid chromatography with fluorescence detection. J Chromatogr B. 2003;798:211-215.
de Santana FJ, Cesarino EJ, Bonato PS. New method for the chiral evaluation ofmirtazapine in human plasma by liquid chromatography. J Chromatogr B. 2004;809:351-356.
Mandrioli R, Pucci V, Sabbioni C, Bartoletti C, Fanali S, Raggi MA. Enantioselective determination of the novel antidepressant mirtazapine and its active demethylated metabolite in human plasma by means of capillary electrophoresis. J Chromatogr A. 2004;1051:253-260.
Fanali S, Aturki Z, Kasicka V, Raggi MA, D'Orazio G. Enantiomeric separation of mirtazapine and its metabolites by nano-liquid chromatography with UV-absorption and mass spectrometric detection. J Sep Sci. 2005;28:1719-1728.
Mandrioli R, Raggi MA. Advances in the enantioseparation of second-generation antidepressant drugs by electrodriven methods. Electrophoresis. 2006;27:213-221.
Niho T, Ito C, Shibutani Y, Hashizume H, Yamaguchi K. Pharmacological properties of MO-8282: a novel antidepressant. Jpn J Pharmacol. 1986;88:309-320.
Mizota M, Oikawa Y, Nakayama K, et al. Pharmacological studies of MO-8282: a new antidepressant. Jpn J Pharmacol. 1986;88:457-466.
Przegaliński E, Baran L, Siwanowicz J, Rawłów A. The lack of antidepressant properties and a potent central antiserotonin activity of Org 8282. Pol J Pharmacol Pharm. 1986;38:377-384.
Matsumoto S. Effect of setiptiline maleate, an antidepressant, on the activities of human liver cytochrome P450 - comparison with fluvoxamine maleate. Jpn Pharmacol Ther. 2001;29:45-50.
Makoto K, Annri A, Noboru Y, et al. The effect of age on plasma level of setiptiline maleate in depressed patients. Prog Neuro-Psychoph. 1994;18:1015-1026.
Brenner E, Baldwin RM, Tamagnan G. Asymetric synthesis of (+)-(S,S)- Reboxetine via a new (S)-2-2(Hydroxymethyl)morpholine preparation. Org Lett. 2005;7:937-939.
Page ME. The promises and pitfalls of reboxetine. CNS Drug Rev. 2003;9:327-342.
Hajos M, Fleishaker JC, Filipiak-Reisner JK, Brown MT, Wong EHF. The selective norepinephrine reuptake inhibitor antidepressant reboxetine: pharmacological and clinical profile. CNS Drug Rev. 2004;10:23-44.
Fleishaker JC. Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression. Clin Pharmacokin. 2000;39:413-427.
De Vane CL, Boulton DW. Great expectations in stereochemistry: Focus on antidepressants. CNS Spectr. 2002;7:28-33.
Fleishaker JC, Mucci M, Pellizzoni C, Poggesi I. Absolute bioavailability of reboxetine enantiomers and effect of gender on pharmacokinetics. Biopharm Drug Dispos. 1999;20:53-57.
Wienkers LC, Allievi C, Hauer MJ, Wynalda MA. Cytochrome P450- mediated metabolism of the individual enantiomers of the antidepressant agent reboxetine in human liver microsomes. Drug Metab Dispos. 1995;27:1334-1340.
Hysek CM, Simmler LD, Ineichen M, et al. The norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA (ecstasy) in humans. Clin Pharm Ther. 2011;90:246-255.
Schüle C, Baghai T, Laakmann G. Mirtazapine decreases stimulatory effects of reboxetine on cortisol, adrenocorticotropin and prolactin secretion in healthy male subjects. Neuroendocrinology. 2004;79:54-62.
Kuhn UD, Kirsch M, Merkel U, et al. Reboxetine and cytochrome P450 - comparison with paroxetine treatment in humans. Int J Clin Pharm Ther. 2007;45:36-46.
Spina E, Avenoso A, Scordo MG, Ancione M, Madia A, Levita A. No effect of reboxetine on plasma concentrations of clozapine, risperidone, and their active metabolites. Ther Drug Monit. 2001;23:675-678.
Serretti A, Lucca A, Cusin C, Smeraldi E. Effect of reboxetine augmentation in SSRI resistant patients. Giorn Ital Psicopat. 2001;7:9-14.
Popławska M, Wróblewska D, Borowicz KK. Interactions between an antidepressant reboxetine and four classic antiepileptic drugs in the mouse model of myoclonic seizures. Pharmacol Rep. 2015;67:1141-1146.
Borowicz KK, Zarczuk R, Latalski M, Borowicz KM. Reboxetine and its influence on the action of classical antiepileptic drugs in the mouse maximal electroshock model. Pharmacol Rep. 2014;66:430-435.
Öhman D, Norlander B, Peterson C, Bengtsson F. Bioanalysis of racemic reboxetine and its desethylated metabolite in a therapeutic drug monitoring setting using solid phase extraction and HPLC. Ther Drug Monit. 2001;23:27-34.
Frigerio E, Pianezzola E, Strolin Benedetti M. Sensitive procedure for the determination of reboxetine enantiomers in human plasma by reversed-phase high-performance liquid chromatography with fluorimetric detection after chiral derivatization with (+)-1-(9-fluorenyl)ethyl chloroformate. J Chromatogr A. 1994;660:351-358.
Walters RR, Buist SC. Improved enantioselective method for the determination of the enantiomers of reboxetine in plasma by solid-phase extraction, chiral derivatization, and column-switching high-performance liquid chromatography with fluorescence detection. J Chromatogr A. 1998;828:167-176.
Khalil NY. A highly sensitive HPLC method with automated on-line sample pre-treatment and fluorescence detection for determination of reboxetine in human plasma. Talanta. 2010;80:1251-1256.
Härtter S, Weigmann H, Hiemke C. Automated determination of reboxetine by high-performance liquid chromatography with column-switching and ultraviolet detection. J Chromatogr B. 2000;740:135-140.
Edwards DM, Pellizzoni C, Breuel HP, et al. Pharmacokinetics of reboxetine in healthy volunteers. Single oral doses, linearity and plasma protein binding. Biopharm Drug Dispos. 1995;16:443-460.
Öhman D, Norlander B, Peterson C, Bengtsson F. Simultaneous determination of reboxetine and O-desethylreboxetine enantiomers using enantioselective reversed-phase high-performance liquid chromatography. J Chromatogr A. 2002;947:247-254.
Déglon J, Lauer E, Thomas A, Mangin P, Staub C. Use of the dried blood spot sampling process coupled with fast gas chromatography and negative-ion chemical ionization tandem mass spectrometry: application to fluoxetine, norfluoxetine, reboxetine, and paroxetine analysis. Anal Bioanal Chem. 2010;396:2523-2532.
Fleishaker JC, Francom SF, Herman BD, Knuth DW, Azie NE. Lack of effect of reboxetine on cardiac repolarization. Clin Pharmacol Ther. 2001;70:261-269.
Öhman D, Cherma MD, Norlander B, Bengtsson F. Determination of serum reboxetine enantiomers in patients on chronic medication with racemic reboxetine. Ther Drug Monit. 2003;25:174-182.
Zoerner AA, Schroeder C, Kayacelebi AA, et al. A validated, rapid UPLC-MS/MS method for simultaneous ivabradine, reboxetine, and metoprolol analysis in human plasma and its application to clinical trial samples. J Chromatogr B. 2013;927:105-111.
Raggi MA, Mandrioli R, Sabbioni C, Parenti C, Cannazza G, Fanali S. Separation of reboxetine enantiomers by means of capillary electrophoresis. Electrophoresis. 2002;23:1870-1877.
Ficarra R, Calabrò ML, Tommasini S, Melardi S, Cutroneo P, Ficarra P. Direct separation of the enantiomers of reboxetine by liquid chromatography on different cellulose- and amylose-based chiral stationary phases. Chromatographia. 2001;53:261-265.
Cannazza G, Braghiroli D, Carrozzo MM, et al. Enantioseparation of the antidepressant reboxetine. J Pharmaceut Biomed. 2008;48(3):991-996.
Lemke TL, Williams DA, eds. (Eds.). Foye's Principles of Medicinal Chemistry 6th Edition Baltimore and Philadelphia; Lippincott Williams & Wilkins: 2008.
Roers E, Adewole T, Johnson JK, Brittain ST. Single and multiple ascending dose study to evaluate the safety, tolerability, and cardiac safety of extended-release viloxazine (SPN-812 ER) in healthy adult subjects. http://www.psychiatrist.com/ascpabstracts/documents/ascpabstracts.pdf. Accessed September 15, 2019.
Blackburn TP, Foster GA, Greenwood DT, Howe R. Effects of viloxazine, its optical isomers and its major metabolites on biogenic amine uptake mechanisms in vitro and in vivo. Eur J Pharmacol. 1978;52:367-374.
Danchev ND, Rozhanets VV, Zhmurenko LA, Glozman OM, Zagorevskiĭ VA. Behavioral and radioreceptor analysis of viloxazine stereoisomers. Bull Exp Biol Med. 1984;97:576-578.
Case DE, Reeves PR. The disposition and metabolism of ECI 58,834 (viloxazine) in humans. Xenobiotica. 1975;5:113-129.
Badolo L, Jensen B, Säll C, Norinder U, Kallunki P, Montanari D. Evaluation of 309 molecules as inducers of CYP3A4:CYP2B6:CYP1A2:OATP1B1:OCT1:MDR1:MRP2:MRP3 and BCRP in cryopreserved human hepatocytes in sandwich culture. Xenobiotica. 2015;45:177-187.
Wang B, Zhou SF. Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem. 2009;16:4066-4218.
Pisani F, Narbone MC, Fazio A, et al. Effect of viloxazine on serum carbamazepine levels in epileptic patients. Epilepsia. 1984;25:482-485.
Pisani F, Fazio A, Artesi C, et al. Elevation of plasma phenytoin by viloxazine in epileptic patients: a clinically significant drug interaction. J Neurol Neurosurg Psychiatry. 1992;55:126-127.
Pisani F, Fazio A, Oteri G, et al. Effects of the antidepressant drug viloxazine on oxcarbazepine and its hydroxylated metabolites in patients with epilepsy. Acta Neurol Scand. 1994;90:130-132.
Odou P, Geronimi-Ferret D, Degen P, Robert H. Viloxazine-carbamazepine. Dangerous double-interaction? One case study. J Pharm Clin. 1996;15:157-160.
Pleece SA, Kirby MJ, Redfern PH. The effect of viloxazine on drug-induced inhibition of food intake in the rat. J Pharm Pharmacol. 1980;32:558-560.
Norman TR, Burrows GD, Davies BM, Maguire KP, Wurm JM. Viloxazine plasma concentrations and clinical response. J Affect Disord. 1980;2:157-164.
Falcy M, Riboulet-Delmas G, Efthymiou ML. Acute poisoning by viloxazine chlorhydrate taken by itself. Encephale. 1983;9:137-144.
Jourdil NH, Fontanille PD, Bessard GM. Concurrent determination of second-generation anti-depressants in plasma by using gas chromatography with nitrogen-phosphorus detection. Clin Chem. 1997;43:2209-2210.
Martínez MA, Sánchez de la Torre C, Almarza E. Simultaneous determination of viloxazine, venlafaxine, imipramine, desipramine, sertraline, and amoxapine in whole blood: comparison of two extraction/cleanup procedures for capillary gas chromatography with nitrogen-phosphorus detection. J Anal Toxicol. 2002;26:296-302.
Fazio A, Crisafulli P, Primerano G, D'Agostino AA, Oteri G, Pisani F. A sensitive gas chromatographic assay for the determination of serum viloxazine concentration using a nitrogen-phosphorus-selective detector. Ther Drug Monit. 1984;6:484-488.
Wille SMR, De Letter EA, Piette MHA, Van Overschelde LK, Van Peteghem CH, Lambert WE. Determination of antidepressants in human postmortem blood, brain tissue, and hair using gas chromatography-mass spectrometry. Int J Legal Med. 2009;123:451-458.
Wille SMR, Van Hee P, Neels HM, Van Peteghem CH, Lambert WE. Comparison of electron and chemical ionization modes by validation of a quantitative gas chromatographic-mass spectrometric assay of new generation antidepressants and their active metabolites in plasma. J Chromatogr A. 2007;1176:236-245.
Titier K, Castaing N, Le-Déodic M, Le-Bars D, Moore N, Molimard M. Quantification of tricyclic antidepressants and monoamine oxidase inhibitors by high-performance liquid chromatography-tandem mass spectrometry in whole blood. J Anal Toxicol. 2007;31:200-207.
Duverneuil C, De la Grandmaison GL, De Mazancourt P, Alvarez JC. A high-performance liquid chromatography method with photodiode-array UV detection for therapeutic drug monitoring of the nontricyclic antidepressant drugs. Ther Drug Monit. 2003;25:565-573.
Tracqui A, Kintz P, Kreissig P, Mangin P. A simple and rapid method for toxicological screening of 25 antidepressants in blood or urine using high performance liquid chromatography with diode-array detection. Ann Biol Clin. 1992;50:639-647.
Garrido EMPJ, Garrido JMPJ, Esteves M, Santos-Silva A, Marques MPM, Borges F. Voltammetric and DFT studies on viloxazine: analytical application to pharmaceuticals and biological fluids. Electroanalysis. 2008;20:1454-1462.
Ogura C, Kishimoto A, Kunimoto N, et al. Clinical pharmacology of a new antidepressant, Y-8894 in healthy young and elderly volunteers. Br J Clin Pharmacol. 1987;23:537-543.
Saka C. Analytical strategies for the determination of norepinephrine reuptake inhibitors in pharmaceutical formulations and biological fluids. Crit Rev Anal Chem. 2016;46:40-66.
Orlando R, Benvenuti C, Mazzo M, Palatini P. The pharmacokinetics of teniloxazine in healthy subjects and patients with hepatic cirrhosis. Br J Clin Pharmacol. 1995;39:445-448.
American Society of Health-System Pharmacists. Atomoxetine hydrochloride. https://www.drugs.com/monograph/atomoxetine-hydrochloride.html. Accessed September 15, 2019.
Huang KL, Wei HT, Hsu JW, et al. Risk of suicide attempts in adolescents and young adults with attention-deficit hyperactivity disorder: a nationwide longitudinal study. Br J Psychiat. 2018;212:234-238.
Kim S-H, Byeon J-Y, Kim Y-H, et al. Physiologically based pharmacokinetic modelling of atomoxetine with regard to CYP2D6 genotypes. Sci Rep. 2018;8:8.
Sauer JM, Ponsler GD, Mattiuz EL, et al. Disposition and metabolic fate of atomoxetine hydrochloride: the role of CYP2D6 in human disposition and metabolism. Drug Metab Dispos. 2003;31:98-107.
Sauer JM, Ring BJ, Witcher JW. Clinical pharmacokinetics of atomoxetine. Clin Pharmacokin. 2005;44:571-590.
Ring BJ, Gillespie JS, Eckstein JA, Wrighton SA. Identification of the human cytochromes P450 responsible for atomoxetine metabolism. Drug Metab Dispos. 2002;30:319-323.
Dinh JC, Pearce RE, Van Haandel L, Gaedigk A, Leeder JS. Characterization of atomoxetine biotransformation and implications for development of PBPK models for dose individualization in children. Drug Metab Dispos. 2016;44:1070-1079.
Todor I, Popa A, Neag M, et al. Evaluation of the potential pharmacokinetic interaction between atomoxetine and fluvoxamine in healthy volunteers. Pharmacology. 2017;99:84-88.
Todor I, Popa A, Neag M, et al. Evaluation of a potential metabolism-mediated drug-drug interaction between atomoxetine and bupropion in healthy volunteers. J Pharm Pharm Sci. 2016;19:198-207.
Belle DJ, Ernest CS, Sauer J-M, Smith BP, Thomasson HR, Witcher JW. Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics. J Clin Pharmacol. 2002;42:1219-1227.
Todor I, Popa A, Neag M, et al. The influence of paroxetine on the pharmacokinetics of atomoxetine and its main metabolite. Clujul Med. 2015;88:513-520.
Sauer JM, Long AJ, Ring B, et al. Atomoxetine hydrochloride: clinical drug-drug interaction prediction and outcome. J Pharmacol Exp Ther. 2004;308:410-418.
Kasi PM, Mounzer R, Gleeson GH. Side effects of atomoxetine and its interactions with inhibitors of the cytochrome P450 system. Case Rep Med. 2011;2011:952584.
Naguy A, Al-Mutairi H, Al-Tajali A. Atomoxetine-related takotsubo cardiomyopathy. J Psychiat Pract. 2016;22:232-233.
Hazell P, Becker K, Nikkanen EA, et al. Relationship between atomoxetine plasma concentration, treatment response and tolerability in attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder. Atten Defic Hyperact Disord. 2009;1:201-210.
Marchei E, Papaseit E, Garcia-Algar OQ, Farrè M, Pacifici R, Pichini S. Determination of atomoxetine and its metabolites in conventional and non-conventional biological matrices by liquid chromatography-tandem mass spectrometry. J Pharmaceut Biomed. 2012;60:26-31.
Papaseit E, Marchei E, Mortali C, et al. Development and validation of a liquid chromatography-tandem mass spectrometry assay for hair analysis of atomoxetine and its metabolites: application in clinical practice. Forensic Sci Int. 2012;218:62-67.
Mullen JH, Shugert RL, Ponsler GD, et al. Simultaneous quantification of atomoxetine as well as its primary oxidative and O-glucuronide metabolites in human plasma and urine using liquid chromatography tandem mass spectrometry (LC/MS/MS). J Pharmaceut Biomed. 2005;38:720-733.
Choi CI, Jang CG, Bae JW, Lee SY. Validation of an analytical LC-MS/MS method in human plasma for the pharmacokinetic study of atomoxetine. J Anal Chem. 2013;68:986-991.
Appel DI, Brinda B, Markowitz JS, Newcorn JH, Zhu H-J. A liquid chromatography/tandem mass spectrometry assay for the analysis of atomoxetine in human plasma and in vitro cellular samples. Biomed Chromatogr. 2012;26(11):1364-1370.
Stegmann B, Dörfelt A, Haen E. Quantification of methylphenidate, dexamphetamine, and atomoxetine in human serum and oral fluid by HPLC with fluorescence detection. Ther Drug Monit. 2016;38:98-107.
Tatar Ulu S. Sensitive high performance liquid chromatographic method for determination of atomoxetine in plasma and urine precolumn derivatization with 1-dimethylaminonaphthalene-5-sulphonyl chloride. J Liq Chromatogr. 2012;35:747-756.
Zhu H-J, Wang J-S, Donovan JL, DeVane CL, Gibson BB, Markowitz JS. Sensitive quantification of atomoxetine in human plasma by HPLC with fluorescence detection using 4-(4,5-diphenyl-1H-imidazole-2-yl) benzoyl chloride derivatization. J Chromatogr B. 2007;846:351-354.
Guo W, Li W, Guo G, et al. Determination of atomoxetine in human plasma by a high performance liquid chromatographic method with ultraviolet detection using liquid-liquid extraction. J Chromatogr B. 2007;854:128-134.
Patel C, Patel M, Rani S, Nivsarkar M, Padh HA. New high performance liquid chromatographic method for quantification of atomoxetine in human plasma and its application for pharmacokinetic study. J Chromatogr B. 2007;850(1-2):356-360.
Kashani J, Ruha A-M. Isolated atomoxetine overdose resulting in seizure. J Emerg Med. 2007;32:175-178.
Garside D, Ropero-Miller JD, Riemer EC. Postmortem tissue distribution of atomoxetine following fatal and nonfatal doses - three case reports. J Forensic Sci. 2006;51:179-182.
Zeng H-J, Yang R, Zhang Y, Li J-J, Qu L-B. Capillary electrophoresis coupled with electrochemiluminescence for determination of atomoxetine hydrochloride and the study on its interactions with three proteins. Luminescence. 2015;30:124-130.
Kalgutkar AS, Vaz ADN, Lame ME, et al. Hop CECA. Bioactivation of the nontricyclic antidepressant nefazodone to a reactive quinone-imine species in human liver microsomes and recombinant cytochrome P450 3A4. Drug Metab Dispos. 2005;33:243-253.
Li AC, Shou WZ, Mai TT, Jiang X-Y. Complete profiling and characterization of in vitro nefazodone metabolites using two different tandem mass spectrometric platforms. Rapid Commun Mass Spectrom. 2007;21:4001-4008.
Mayol RF, Cole CA, Luke GM, Colson KL, Kerns EH. Characterization of the metabolites of the antidepressant drug nefazodone in human urine and plasma. Drug Metab Dispos. 1994;22:304-311.
Mercolini L, Colliva C, Amore M, Fanali S, Raggi MA. HPLC analysis of the antidepressant trazodone and its main metabolite m-CPP in human plasma. J Pharmaceut Biomed. 2008;47:882-887.
Rotzinger S, Baker GB. Human CYP3A4 and the metabolism of nefazodone and hydroxynefazodone by human liver microsomes and heterologously expressed enzymes. Eur Neuropsychopharmacol. 2002;12:91-100.
Von Moltke LL, Zalma A, Granda BW, Grassi JM, Shader RI, Greenblatt DJ. Meta-chloro-phenylpiperazine (mCPP): P450-3A-dependent formation from nefazodone and trazodone; P450-2D6-dependent clearance. Clin Pharm Ther. 1999;65:144. -144.
Preskorn SH, Catterson ML. General principles of pharmacokinetics. In: Preskorn SH, Stanga CY, Feighner JP, Ross R, eds. Antidepressants: Past, Present and Future. Berlin and Heidelberg: Springer; 2004.
DeVane CL, Donovan JL, Liston HL, et al. Comparative CYP3A4 inhibitory effects of venlafaxine, fluoxetine, sertraline, and nefazodone in healthy volunteers. J Clin Psychopharmacol. 2004;24:4-10.
Abernethy DR, Barbey JT, Franc J, et al. Loratadine and terfenadine interaction with nefazodone: both antihistamines are associated with QTc prolongation. Clin Pharm Ther. 2001;69:96-103.
Kotlyar M, Brewer ER, Golding M, Carson SW. Nefazodone inhibits methylprednisolone disposition and enhances its adrenal-suppressant effect. J Clin Psychopharmacol. 2003;23:652-656.
Taylor D, Bodani M, Hubbeling A, Murray R. The effect of nefazodone on clozapine plasma concentrations. Int Clin Psychopharmacol. 1999;14:185-187.
Marino MR, Langenbacher KM, Hammett JL, Nichola P, Uderman HD. The effect of nefazodone on the single-dose pharmacokinetics of phenytoin in healthy male subjects. J Clin Psychopharmacol. 1997;17:27-33.
Dockens RC, Greene DS, Barbhaiya RH. Assessment of pharmacokinetic and pharmacodynamic drug interactions between nefazodone and digoxin in healthy male volunteers. J Clin Pharmacol. 1996;36:160-167.
Barbhaiya RH, Shukla UA, Greene DS, Breuel H-P, Midha KK. Investigation of pharmacokinetic and pharmacodynamic interactions after coadministration of nefazodone and haloperidol. J Clin Psychopharmacol. 1996;16:26-34.
Mandrioli R, Mercolini L, Raggi MA. Benzodiazepine metabolism: an analytical perspective. Curr Drug Metab. 2008;9:827-844.
Greene DS, Salazar DE, Dockens RC, Kroboth P, Barbhaiya RH. Coadministration of nefazodone and benzodiazepines: III. A pharmacokinetic interaction study with alprazolam. J Clin Psychopharmacol. 1995;15:399-408.
Barbhaiya RH, Shukla UA, Kroboth PD, Greene DS. Coadministration of nefazodone and benzodiazepines: II. A pharmacokinetic interaction study with triazolam. J Clin Psychopharmacol. 1995;15:320-326.
Lam YWF, Alfaro CL, Ereshefsky L, Miller M. Pharmacokinetic and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone. J Clin Pharmacol. 2003;43(11):1274-1282.
Greene DS, Salazar DE, Dockens RC, Kroboth P, Barbhaiya RH. Coadministration of nefazodone and benzodiazepines: IV. A pharmacokinetic interaction study with lorazepam. J Clin Psychopharmacol. 1995;15:409-416.
Khan AY, Preskorn SH, Horst WD. Coadministration of nefazodone and desipramine: a pharmacokinetic interaction study. J Pak Med Ass. 2007;57:230-235.
Laroudie C, Salazar DE, Cosson J-P, et al. Pharmacokinetic evaluation of co-administration of nefazodone and lithium in healthy subjects. Eur J Clin Pharmacol. 1999;54:923-928.
Marcucci C, et al, ed. A Case Approach to Perioperative Drug-Drug Interactions. Berlin and Heidelberg: Springer; 2015:767.
Michalski LS, Bhuva D, Pakrasi A, Holt DR, Hou SH. Sirolimus and nefazodone interaction in a renal transplant patient. Eur J Psychiat. 2011;25:119-121.
Hagan JB, Erickson D, Singh RJ. Triamcinolone acetonide induced secondary adrenal insufficiency related to impaired CYP3A4 metabolism by coadministration of nefazodone. Pain Med. 2010;11:1132-1135.
Alderman CP, Gebauer MG, Gilbert AL, Condon JT. Possible interaction of zopiclone and nefazodone. Ann Pharmacother. 2001;35:1378-1380.
Yao M, Srinivas NR. Simultaneous quantitation of d7-nefazodone, nefazodone. d7-hydroxynefazodone, hydroxynefazodone, m-chlorophenylpiperazine and triazole-dione in human plasma by liquid chromatographic-mass spectrometry. Biomed Chromatogr. 2000;14:106-112.
Burke MJ, Preskorn SH. Therapeutic drug monitoring of antidepressants. In: Preskorn SH, Stanga CY, Feighner JP, Ross R, eds. Antidepressants: Past, Present and Future. Berlin and Heidelberg: Springer; 2004.
Barbhaiya RH, Buch AB, Greene DS. A study of the effect of age and gender on the pharmacokinetics of nefazodone after single and multiple doses. J Clin Psychopharmacol. 1996;16:19-25.
Mao Y, Huang M-Q, Xia Y-Q, Jemal M. High-throughput quantitation of nefazodone and its metabolites in human plasma by high flow direct-injection LC-MS/MS. J Pharmaceut Biomed. 2007;43:1808-1819.
Yao M, Shah VR, Shyu WC, Srinivas NR. Sensitive liquid chromatographic-mass spectrometric assay for the simultaneous quantitation of nefazodone and its metabolites hydroxynefazodone m-chlorophenylpiperazine and triazole-dione in human plasma using single-ion monitoring. J Chromatogr B. 1998;718:77-85.
Dodd S, Buist A, Burrows GD, Maguire KP, Norman TR. Determination of nefazodone and its pharmacologically active metabolites in human blood plasma and breast milk by high-performance liquid chromatography. J Chromatogr B. 1999;730:249-255.
Franc JE, Duncan GF, Farmen RH, Pittman KA. High-performance liquid chromatographic method for the determination of nefazodone and its metabolites in human plasma using laboratory robotics. J Chromatogr B. 1991;570:129-138.
Bjork H, Bengtsson F. A simple method for routine therapeutic drug monitoring of the novel antidepressant nefazodone and its main metabolite m-chlorophenylpiperazine in serum with high-performance liquid chromatography. Nord J Psychiat. 1998;52:117.
Franklin M. Determination of nefazodone and its metabolises in plasma by high-performance liquid chromatography with coulometric detection. J Pharmaceut Biomed. 1993;11:1109-1113.
Zlotos DP. Recent progress in the development of agonists and antagonists for melatonin receptors. Curr Med Chem. 2012;19:3532-3549.
Fasipe OJ. Neuropharmacological classification of antidepressant agents based on their mechanisms of action. Arch Med Health Sci. 2018;6:81-94.
European Medicines Agency. Valdoxan (agomelatine). www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000915/human_med_001123.jsp&mid=WC0b01ac058001d124. Accessed September 10, 2019.
Pae C-U. Agomelatine: a new option for treatment of depression? Exp Opin Pharmacother. 2014;15:443-447.
Gahr M, Kratzer W, Fuchs M, Connemann BJ. Safety and tolerability of agomelatine: focus on hepatotoxicity. Curr Med Chem. 2014;15:694-702.
Australian Therapeutic Goods Administration. Australian Public Assessment Report for Agomelatine. https://www.tga.gov.au/sites/default/files/auspar-valdoxan.pdf. Accessed September 15, 2019
Dubocovich ML. Drug evaluation: agomelatine targets a range of major depressive disorder symptoms. Curr Opin Investig Drugs. 2006;7:670-680.
Hardeland R. Agomelatine and the risk of hepatotoxicity. J Sympt Signs. 2014:3341-3346.
Liu X, Lu Y-F, Guan X, Zhao M, Wang J, Li F. Characterizing novel metabolic pathways of melatonin receptor agonist agomelatine using metabolomic approaches. Biochem Pharmacol. 2016;109:70-82.
Saiz-Rodríguez M, Ochoa D, Belmonte C, et al. Polymorphisms in CYP1A2:CYP2C9 and ABCB1 affect agomelatine pharmacokinetics. J Psychopharmacol. 2019;33:522-531.
Spina E, Trifirò G, Caraci F. Clinically significant drug interactions with newer antidepressants. CNS Drugs. 2012;26:39-67.
EMC, Electronic Medicines Compendium. Valdoxan 25 mg film-coated tablets. https://www.medicines.org.uk/emc/product/6564/smpc. Accessed September 15, 2019
Štuhec M. Excessive sweating induced by interaction between agomelatine and duloxetine hydrochloride: case report and review of the literature. Wien Klin Wochensch. 2015;127:703-706.
Imboden C, Hatzinger M. Agomelatine-induced akathisia with concomitant duloxetine medication: a case report. Pharmacopsychiatry. 2012;45:162.
Mercolini l, Mandrioli R, Trerè T, Bugamelli F, Ferranti A, Raggi MA. Fast CE analysis of adrenergic amines in different parts of Citrus aurantium fruit and dietary supplements. J Sep Sci. 2010;33:2520-2527.
Nadar JS, Kale PP, Kadu PK, Prabhavalkar K, Dhangar R. Potentiation of antidepressant effects of agomelatine and bupropion by hesperidin in mice. Neurol Res Int. 2018;2018:1-7.
Song L, Du Q, Jiang X, Wang L. Effect of CYP1A2 polymorphism on the pharmacokinetics of agomelatine in Chinese healthy male volunteers. J Clin Pharm Ther. 2014;39:204-209.
Li C, Xu J, Zheng Y, et al. Bioequivalence and pharmacokinetic profiles of agomelatine 25-mg tablets in healthy Chinese subjects: a four-way replicate crossover study demonstrating high intra-and inter-individual variations. Chem Pharm Bull. 2017;65:524-529.
Song L, Wang M, Wen A, et al. Determination of agomelatine in human plasma by LC-MS/MS: application to a pharmacokinetic study in Chinese volunteers. J China Pharm Univ. 2014;45:698-702.
Ogawa T, Iwai M, Hattori H, et al. High-throughput analysis of ramelteon, agomelatine, and melatonin in human plasma by ultra-performance liquid chromatography-tandem mass spectrometry. Forensic Toxicol. 2014;32:126-131.
Wang X, Zhang D, Liu M, et al. LC-MS/MS method for the determination of agomelatine in human plasma and its application to a pharmacokinetic study. Biomed Chromatogr. 2014;28:218-222.
Patil SR, Nerurkar KK, Kalamkar AM, Pukale V, Mangaonkar KV, Pingale SG. Validated LC-MS/MS method for quantification of agomelatine in human plasma and its application in a pharmacokinetic study. J Mass Spectrom. 2012;47:23-28.
Cheng J, He J, Mao X, Zhou Q, Zhang M, Zhang H. Concentration determination of agomelatine in human plasma and its pharmacokinetics study. Pharm Care Res. 2018;18:199-202.
Li M, Tang F, Xie F, et al. Development and validation a LC-MS/MS method for the simultaneous determination of agomelatine and its metabolites, 7-desmethyl-agomelatine and 3-hydroxy-agomelatine in human plasma: application to a bioequivalence study. J Chromatogr B. 2015;1003:60-66.
Saracino MA, Mercolini L, Carbini G, et al. Multi-matrix assay of the first melatonergic antidepressant agomelatine by combined liquid chromatography-fluorimetric detection and microextraction by packed sorbent. J Pharmaceut Biomed. 2014;95:61-67.
Lerman C, Niaura R, Collins BN, et al. Effect of bupropion on depression symptoms in a smoking cessation clinical trial. Psychol Addict Behav. 2004;18:362-366.
Crooks PA, Bardo MT, Dwoskin LP. Nicotinic receptor antagonists as treatments for nicotine abuse. Adv Pharmacol. 2014;69:513-551.
Gartlehner G, Thieda P, Hansen RA, et al. Comparative risk for harms of second-generation antidepressants: a systematic review and meta-analysis. Drug Saf. 2008;31:851-865.
Masters AR, Gufford BT, Lu JBL, Metzger IF, Jones DR, Desta Z. Chiral plasma pharmacokinetics and urinary excretion of bupropion and metabolites in healthy volunteers. J Pharmacol Exp Ther. 2016;358:230-238.
Xue C, Zhang X, Cai W. Prediction of drug-drug interactions with bupropion and its metabolites as CYP2D6 inhibitors using a physiologically-based pharmacokinetic model. Pharmaceutics. 2018;10:E1.
Benowitz NL, Zhu AZX, Tyndale RF, Dempsey D, Jacob P. Influence of CYP2B6 genetic variants on plasma and urine concentrations of bupropion and metabolites at steady state. Pharmacogenet Genomics. 2013;23:135-141.
Sager JE, Choiniere JR, Chang J, Stephenson-Famy A, Nelson WL, Isoherranen N. Identification and structural characterization of three new metabolites of bupropion in humans. ACS Med Chem Lett. 2016;7:791-796.
Hesse LM, Venkatakrishnan K, Court MH, et al. CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos. 2000;28:1176-1183.
Paslakis G, Gilles M, Deuschle M. Clinically relevant pharmacokinetic interaction between venlafaxine and bupropion: a case series. J Clin Psychopharmacol. 2010;30:473-474.
Nirogi R, Palacharla RC, Mohammed AR, Manoharan A, Ponnamaneni RK, Bhyrapuneni G. Evaluation of metabolism dependent inhibition of CYP2B6 mediated bupropion hydroxylation in human liver microsomes by monoamine oxidase inhibitors and prediction of potential as perpetrators of drug interaction. Chem-Biol Interact. 2015;230:9-20.
Sager JE, Tripathy S, Price LS,L, et al. In vitro to in vivo extrapolation of the complex drug-drug interaction of bupropion and its metabolites with CYP2D6; simultaneous reversible inhibition and CYP2D6 downregulation. Biochem Pharmacol. 2017;123:85-96.
Reese MJ, Wurm RM, Muir KT, et al. An in vitro mechanistic study to elucidate the desipramine/bupropion clinical drug-drug interaction. Drug Metab Dispos. 2008;36:1198-1201.
Popli AP, Tanquary J, Lamparella V, Masand PS. Bupropion and anticonvulsant drug interactions. Ann Clin Psychiat. 1995;7:99-101.
Hsyu P-H, Singh A, Giargiari TD, Johnston JA. Pharmacokinetics of bupropion and its metabolites in smokers and non-smokers. Clin Pharm Ther. 1997;61:180-183.
Hesse LM, Von Moltke LL, Shader RI, Greenblatt DJ. Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: Potential drug interactions with bupropion. Drug Metab Dispos. 2001;29:100-102.
McCollum DL, Greene JL, McGuire DK. Severe sinus bradycardia after initiation of bupropion therapy: a probable drug-drug interaction with metoprolol. Cardiovasc Drug Ther. 2004;18:329-330.
Shad MU, Preskorn SH. A possible bupropion and imipramine interaction. J Clin Psychopharmacol. 1997;17:118-119.
Weintraub D. Nortriptyline toxicity secondary to interaction with bupropion sustained-release. Depress Anxiety. 2001;13:50-52.
Chandler P, Herxheimer A. Unexpected aggressive behaviour: interaction of bupropion and alcohol. Int J Risk Saf Med. 2011;23:133-137.
Marcucci C, et al, ed. A Case Approach to Perioperative Drug-Drug Interactions. Berlin and Heidelberg: Springer; 2015:543.
Schmid Y, Rickli A, Schaffner A, et al. Interactions between bupropion and 3,4-methylenedioxymethamphetamine in healthy subjects. J Pharmacol Exp Ther. 2015;353:102-111.
Lewis BR, Aoun SL, Bernstein GA, Crow SJ. Pharmacokinetic interactions between cyclosporine and bupropion or methylphenidate. J Child Adolesc Psychopharmacol. 2001;11:193-198.
Molnari JC, Hassan HE, Moeller BM, Myers AL. Drug interaction study between bupropion and ticlopidine in male CF-1 mice. Biol Pharm Bull. 2011;34:447-451.
Wang J-S, DeVane CL, Gibson BB, Donovan JL, Markowitz JS, Zhu HJ. Population pharmacokinetic analysis of drug-drug interactions among risperidone, bupropion, and sertraline in CF1 mice. Psychopharmacology. 2006;183:490-499.
Tekle A, Al-Khamis KI. Phenytoin-bupropion interaction: effect on plasma phenytoin concentration in the rat. J Pharm Pharmacol. 1990;42:799-801.
Shen Y, Yu Y, Lai W, et al. Evaluation of a potential clinical significant drug-drug interaction between digoxin and bupropion in cynomolgus monkeys. Pharm Res. 2019:36.
He J, Yu Y, Prasad B, Chen X, Unadkat JD. Mechanism of an unusual, but clinically significant, digoxin-bupropion drug interaction. Biopharm Drug Dispos. 2014;35:253-263.
Abrudan MB, Muntean DM, Gheldiu AM, Neag MA, Vlase L. The pharmacokinetic interaction study between carvedilol and bupropion in rats. Pharmacology. 2017;99:139-143.
Gheldiu A-M, Popa A, Neag M, et al. Assessment of a potential pharmacokinetic interaction between nebivolol and bupropion in healthy volunteers. Pharmacology. 2016;98:190-198.
Johnston JA, Fiedler-Kelly J, Glover ED, Sachs DP, Grasela TH, DeVeaugh-Geiss J. Relationship between drug exposure and the effiacy and safety of bupropion sustained release for smoking cessation. Nicotine Tob Res. 2001;3:131-140.
Park S, Park C-S, Lee SJ, et al. Development and validation of a high-performance liquid chromatography-tandem mass spectrometric method for simultaneous determination of bupropion, quetiapine and escitalopram in human plasma. Biomed Chromatogr. 2015;29:612-618.
Parekh JM, Sutariya DK, Vaghela RN, Sanyal M, Yadav M, Shrivastav PS. Sensitive, selective and rapid determination of bupropion and its major active metabolite, hydroxybupropion, in human plasma by LC-MS/MS: application to a bioequivalence study in healthy Indian subjects. Biomed Chromatogr. 2012;26:314-326.
Yeniceli D, Dogrukol-Ak D, An LC. Method for the determination of bupropion and its main metabolite, hydroxybupropion in human plasma. Chromatographia. 2009;70:1703-1708.
Shahi PK, Patel H, Shah V, Bhokari A, Thennati R, Ameta R. Simultaneous quantitative determination of bupropion and its metabolites by high performance liquid chromatography tandem mass spectrometry detection: application to bioequivalence study. Indian J Pharm Ed Res. 52, 2018:S37-S46.
Shah PA, Parekh JM, Shrivastav PS. Assessment of critical extraction and chromatographic parameters for the determination of bupropion and its three primary metabolites in human plasma by LC-MS/MS. Microchem J. 2017;135:81-90.
Borges V, Yang E, Dunn J, Henion J. High-throughput liquid chromatography-tandem mass spectrometry determination of bupropion and its metabolites in human, mouse and rat plasma using a monolithic column. J Chromatogr B. 2004;804:277-287.
Masters AR, McCoy M, Jones DR, Desta Z. Stereoselective method to quantify bupropion and its three major metabolites, hydroxybupropion, erythro-dihydrobupropion, and threo-dihydrobupropion using HPLC-MS/MS. J Chromatogr B. 2016;1015-1016:201-208.
Teitelbaum AM, Flaker AM, Kharasch ED. Development, validation and application of a comprehensive stereoselective LC/MS-MS assay for bupropion and oxidative, reductive, and glucuronide metabolites in human urine. J Chromatogr B. 2016;1027:239-253.
Burleson Daviss W, Perel JM, Brent DA, et al. Acute antidepressant response and plasma levels of bupropion and metabolites in a pediatric-aged sample: an exploratory study. Ther Drug Monit. 2006;28:190-198.
Loboz KK, Gross AS, Ray J, McLachlan AJ. HPLC assay for bupropion and its major metabolites in human plasma. J Chromatogr B. 2005;823:115-121.
Tatar Ulu S, Tuncel M. Determination of bupropion using liquid chromatography with fluorescence detection in pharmaceutical preparations, human plasma and human urine. J Chromatogr Sci. 2012;50:433-439.
Petrides AK, Moskowitz J, Johnson-Davis KL, et al. The development and validation of a turbulent flow-liquid chromatography-tandem mass spectrometric method for the simultaneous quantification of citalopram, sertraline, bupropion and hydroxybupropion in serum. Clin Biochem. 2014;47:73-79.
Wang X, Vernikovskaya DI, Abdelrahman DR, Hankins GDV, Ahmed MS, Nanovskaya TN. Simultaneous quantitative determination of bupropion and its three major metabolites in human umbilical cord plasma and placental tissue using high-performance liquid chromatography-tandem mass spectrometry. J Pharmaceut Biomed. 2012;70:320-329.
Paul R, Schaaff N, Padberg F, Möller HJ, Frodl T. Comparison of racemic ketamine and S-ketamine in treatment-resistant major depression: report of two cases. World J Biol Psychiat. 2009;10:241-244.
Shouan A, Grover S. Adjunctive intranasal esketamine in treatment-resistant depression. JAMA Psychiat. 2018;75:654.
European Medicines Agency. List of nationally authorised medicinal products - active substance: esketamine. https://www.ema.europa.eu/en/documents/psusa/esketamine-list-nationally-authorised-medicinal-products-psusa/00001266/201608_en.pdf. Accessed September 15, 2019
USA Food and Drug Administration. FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor's office or clinic. https://www.fda.gov/news-events/press-announcements/fda-approves-new-nasal-spray-medication-treatment-resistant-depression-available-only-certified. Accessed September 15, 2019
Hashimoto K. Rapid-acting antidepressant ketamine, its metabolites and other candidates: a historical overview and future perspective. Psychiatry Clin Neurosci. 2019;73:613-627.
Ficek J, Zygmunt M, Piechota M, et al. Molecular profile of dissociative drug ketamine in relation to its rapid antidepressant action. BMC Genomics. 2016;17:362.
Janssen Inc. Spravato Prescribing Information. https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/SPRAVATO-pi.pdf. Accessed September 10, 2019.
Hashimoto K, Yang C. Is (S)-norketamine an alternative antidepressant for esketamine? Eur Arch Psychiat Clin Neurosci. 2019;269:867-868.
Fanta S, Kinnunen M, Backman JT, Kalso E. Population pharmacokinetics of S-ketamine and norketamine in healthy volunteers after intravenous and oral dosing. Eur J Clin Pharmacol. 2015;71:441-447.
Ashraf MW, Peltoniemi MA, Olkkola KT, Neuvonen PJ, Saari TI. Semimechanistic population pharmacokinetic model to predict the drug-drug interaction between S-ketamine and ticlopidine in healthy human volunteers. Pharmacometrics Syst Pharmacol. 2018;7:687-697.
Peltoniemi MA, Saari TI, Hagelberg NM, Laine K, Neuvonen PJ, Olkkola KT. St John's wort greatly decreases the plasma concentrations of oral S-ketamine. Fund Clin Pharmacol. 2012;26:743-750.
Hu J-P, Chen H, Li Y. Effect of S(+)-ketamine on liver microsomal cytochrome P450 isozymes in rats. Chin Pharm J. 2008;43:906-909.
European Medicines Agency (EMA) - Committee for Medicinal Products for Human Use (CHMP), Assessment report: Spravato - Procedure No. EMEA/H/C/004535/0000. https://www.ema.europa.eu/en/documents/assessment-report/spravato-epar-public-assessment-report_en.pdf. Accessed January 31, 2020.
Goldberg ME, Torjman MC, Schwartzman RJ, Mager DE, Wainer IW. Enantioselective pharmacokinetics of (R)- and (S)-ketamine after a 5-day infusion in patients with complex regional pain syndrome. Chirality. 2011;23:138-143.
Fassauer GM, Hofstetter R, Hasan M, et al. Ketamine metabolites with antidepressant effects: Fast, economical, and eco-friendly enantioselective separation based on supercritical-fluid chromatography (SFC) and single quadrupole MS detection. J Pharmaceut Biomed. 2017;146:410-419.
Samuels BA, Nautiyal KM, Kruegel AC, et al. The behavioral effects of the antidepressant tianeptine require the mu-opioid receptor. Neuropsychopharmacology. 2017;42:2052-2063.
Uzbekov MG. Antidepressant action of tianeptine is connected with acceleration of serotonin turnover in the synapse: a hypothesis. Neuropsychopharmacol Hung. 2009;11:83-87.
Wlaź P, Kasperek R, Wlaź A, et al. NMDA and AMPA receptors are involved in the antidepressant-like activity of tianeptine in the forced swim test in mice. Pharmacol Rep. 2011;63:1526-1532.
Grislain L, Gele P, Bertrand M, et al. The metabolic pathways of tianeptine, a new antidepressant, in healthy volunteers. Drug Metab Dispos. 1990;18:804-808.
Wilde MI, Benfield P. Tianeptine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depression and coexisting anxiety and depression. Drugs. 1995;49:411-439.
Toon S, Holt BL, Langley SJ, et al. Pharmacokinetic and pharmacodynamic interaction between the antidepressant tianeptine and oxazepam at steady-state. Psychopharmacology. 1990;101:226-232.
Salvadori C, Ward C, Defrance R, Hopkins R. The pharmacokinetics of the antidepressant tianeptine and its main metabolite in healthy humans - influence of alcohol co-administration. Fund Clin Pharmacol. 1990;4:115-125.
Zini R, Morin D, Salvadori C, Tillement JP. The influence of various drugs on the binding of tianeptine to human plasma proteins. Int J Clin Pharmacol Ther Toxicol. 1991;29:64-66.
Borowicz KK, Banach M, Piskorska B, Czuczwar SJ. Effect of acute and chronic tianeptine on the action of classical antiepileptics in the mouse maximal electroshock model. Pharmacol Rep. 2013;65:379-388.
Grasela TH, Fiedler-Kelly JB, Salvadori C, Marey C, Jochemsen R, Loo H. Predictive performance of population pharmacokinetic parameters of tianeptine as applied to plasma concentrations from a post-marketing study. Eur J Clin Pharmacol. 1993;45:123-128.
Szafarz M, Wencel A, Pociecha K, Fedak FA, Wlaź P, Wyska E. Pharmacokinetic study of tianeptine and its active metabolite MC5 in rats following different routes of administration using a novel liquid chromatography tandem mass spectrometry analytical method. N-S Arch Pharmacol. 2018;391:185-196.
Zheng R, Kim B-H. Pharmacokinetic and bioequivalence assessment of two formulations of tianeptine sodium in healthy male volunteers. Int J Clin Pharm Ther. 2014;52:817-823.
Tatar Ulu S. Determination of tianeptine in human plasma using high-performance liquid chromatography with fluorescence detection. J Chromatogr B. 2006;834:62-67.
Gaulier J-M, Marquet P, Lacassie E, Desroches R, Lachatre G. High-performance liquid chromatographic determination of tianeptine in plasma applied to pharmacokinetic studies. J Chromatogr B. 2000;748:407-414.
Nicot G, Lachatre G, Gonnet C, Mallon J, Mocaer E. Ion-pair extraction and high-performance liquid chromatographic determination of tianeptine and its metabolites in human plasma, urine and tissues. J Chromatogr B. 1986;381:115-126.
Gilchrist EEA, Sadler DW. The role of depression in unnatural death: a case-based retrospective study. J Affect Disord. 2019;259:7-14.
Gartlehner G, Hansen RA, Morgan LC, et al. Second-generation antidepressants in the pharmacologic treatment of adult depression: an update of the 2007 comparative effectiveness review. Rockville (MD): Agency for Healthcare Research and Quality (US); 2011. http://www.ncbi.nlm.nih.gov/books/NBK83442/. Accessed October 10, 2019.